PEPTIDES BIO / RESEARCH MODELS &AMP; EVIDENCE

BPC-157 Research on Humans: Verifying the Direct Record

A source-limited inventory of direct BPC-157 human records, separating small published reports from formal registry entries without posted results and preserving material-identity gaps.

Published2026-09-03 Published byPeptides Bio

Research or raw-material evaluation only. Not for human or veterinary use.

BPC-157 research on humans requires a record-by-record audit. A human citation may describe a small pilot, a retrospective chart review, or a registered study with no posted results. Those designs answer different questions and cannot be merged into one estimate of efficacy or safety. This page inventories directly verifiable PubMed and ClinicalTrials.gov records, identifies what each record actually reports, and keeps material identity separate from human outcome claims.

Inclusion rule for a direct human record

The inventory includes peer-reviewed records indexed in PubMed that explicitly report human participants and formal ClinicalTrials.gov entries that name BPC-157 or a BPC-157-containing material. Animal experiments, cell assays, narrative reviews, supplier pages, media summaries, and registry entries without posted results are not used as outcome evidence. A registration can document a planned design and status; it does not become a result report unless a results section is posted.

This is a targeted evidence inventory, not a systematic review. Search coverage, indexing, and registry status can change. Each record must be read within its own population, comparator, outcome collection, follow-up, and material description.

Published record: two-person intravenous pilot

PMID 40131143 describes an IRB-approved pilot at a private Florida clinic with two participants, a 58-year-old man and a 68-year-old woman. The abstract states that both had prior exposure to BPC-157 and that the report collected blood work and vital signs around the clinic observations. No control group is reported.

The authors report no measurable changes in the listed heart, liver, kidney, thyroid, and blood-glucose biomarkers and no reported side effects in these two participants. These are observations from a two-person uncontrolled pilot. They cannot establish population safety, comparative benefit, or a standard administration approach. The abstract does not provide a peptide sequence, analytical identity result, lot number, or batch record for the material called BPC-157. Direct record: PMID 40131143.

Published record: twelve-person symptom report

PMID 39325560 reports 12 women aged 39 to 76 years at a private clinic. The abstract says the participants had not responded to pentosan polysulfate and describes a single clinic procedure followed by a Global Response Assessment questionnaire. It does not describe randomisation, a comparator group, or a defined follow-up duration.

The report presents participant symptom ratings after the procedure and states that no participant dropped out and no adverse events were reported. These are uncontrolled, self-reported observations in a small selected group. They are not a validated efficacy estimate, a safety profile, or a general treatment recommendation. The paper identifies BPC-157 as supplied by a 503A compounding pharmacy, but the abstract does not supply a sequence, purity result, lot, or independent analytical identity record. Direct record: PMID 39325560.

Published record: retrospective knee-pain chart review

PMID 34324435 reports a 2019 to 2020 retrospective chart review from primary care in Orlando, Florida. Seventeen patients were included and 16 were reached by telephone. Follow-up varied, with most reported observations occurring months after the clinic event. Twelve contacted patients were recorded in a BPC-157-only subgroup and four in a subgroup that also involved thymosin-beta-4 (TB4).

Participants gave retrospective ratings about pain and perceived change. The abstract says that specific tools for function, quality of life, stiffness, and daily activities were not used. The mixed BPC-157/TB4 subgroup cannot be treated as a BPC-157-only comparison. Recall bias, variable follow-up, absence of a control group, small subgroups, and missing sequence or lot information limit what the record can support. It is not evidence of a causal effect or material equivalence across products. Direct record: PMID 34324435.

Registry layer: planned designs without posted results

ClinicalTrials.gov NCT02637284 describes a phase I pilot in healthy volunteers for PCO-02, whose title identifies BPC-157 as an active ingredient. The record lists a placebo-controlled design, planned enrollment of 42, and adverse-event follow-up. Its status is Unknown, with a last update recorded in 2015, and no results section is posted. It is evidence of a registered plan, not a verified human outcome. Direct registry record: NCT02637284.

NCT07437547 is listed as Recruiting for a planned randomised, double-blind, placebo-controlled phase 2 study in acute grade II hamstring strain. NCT07752381 is listed as Completed for a 40-participant study of a BPC-157-containing peptide gummy. Neither record has a posted results section. A completed status without posted results cannot be used as an efficacy or safety result, and the gummy material cannot be assumed equivalent to the materials in the published reports. NCT07437547; NCT07752381.

Material identity remains unresolved across records

Across these reports, “BPC-157” appears as a name or active-ingredient statement, but the accessible records do not provide one shared sequence, lot, certificate, or analytical result that establishes material equivalence. The compounding-pharmacy report, the BPC-157/TB4 subgroup, and the BPC-157-containing gummy registry entry introduce different material contexts. A shared name is not enough to combine results or transfer one record’s observation to another material.

For a material audit, record the exact wording, stated source, lot reference, analytical method, and document date. If a field is absent, write not reported in the accessible record. Do not fill an identity gap with a catalogue page or with an animal or in-vitro paper.

What these records can and cannot establish

The direct records support a narrow description of what their authors or registries reported: small uncontrolled or retrospective human observations, plus planned studies with no posted outcomes. They do not establish a treatment effect, a population safety profile, an approved use, a recommended administration method, or a product claim. Human evidence is also not interchangeable with the site’s animal, cell, or narrative literature pages.

When comparing records, keep participant denominator, design, comparator, outcome instrument, follow-up, and material description in separate columns. A registry status is not a result. A self-reported symptom change is not a controlled endpoint. A no-event statement in a tiny pilot is not a safety guarantee. These distinctions are the core of a defensible BPC-157 human evidence record.

Difference from related records

This page targets the exact keyword bpc 157 research on humans by verifying direct human publications and registry entries, then separating study design from outcome and material identity. It differs from #386, which surveys BPC-157 literature and documentation scope; #462, which critiques narrative reviews; #484, which reads an in-vitro AChE paper; and #408, which covers a rat Achilles-tendon model. The related BPC-157 research material page is a catalogue record and does not prove that its material was used in any cited human record.

Direct records and scope

Research scope: This summary reports study and registry details from the cited records and does not provide medical, veterinary, dosing, administration, safety, or treatment guidance. It does not represent a product-use recommendation.

References

Need a product record?

Build a structured request.

Browse materials